LAB Key Statistics, Chart & Performance
The current stock price of LAB is 1.38 USD. In the past month the price decreased by -3.5%. In the past year, price decreased by -24.18%.
LAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.93 | 218.19B | ||
| DHR | DANAHER CORP | 29.87 | 162.69B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 185.88 | 56.48B | ||
| A | AGILENT TECHNOLOGIES INC | 24.8 | 39.23B | ||
| IQV | IQVIA HOLDINGS INC | 19.51 | 38.64B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.94 | 29.01B | ||
| WAT | WATERS CORP | 30.4 | 22.98B | ||
| ILMN | ILLUMINA INC | 30.95 | 20.62B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.8 | 19.73B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.69 | 15.99B | ||
| TEM | TEMPUS AI INC | N/A | 11.15B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B |
Related stock screener links
About LAB
Company Profile
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Company Info
STANDARD BIOTOOLS INC
2 Tower Place, Suite 2000
South San Francisco CALIFORNIA US
Employees: 818
Phone: 16502666000
STANDARD BIOTOOLS INC / LAB FAQ
What does STANDARD BIOTOOLS INC do?
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
What is the current price of LAB stock?
The current stock price of LAB is 1.38 USD. The price decreased by -6.12% in the last trading session.
What is the dividend status of STANDARD BIOTOOLS INC?
LAB does not pay a dividend.
What is the ChartMill technical and fundamental rating of LAB stock?
LAB has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is LAB stock listed?
LAB stock is listed on the Nasdaq exchange.
What is the outstanding short interest for STANDARD BIOTOOLS INC?
The outstanding short interest for STANDARD BIOTOOLS INC (LAB) is 2.91% of its float.
LAB Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LAB. When comparing the yearly performance of all stocks, LAB is a bad performer in the overall market: 76.45% of all stocks are doing better.
LAB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LAB. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LAB Financial Highlights
Over the last trailing twelve months LAB reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 52.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.77% | ||
| ROE | -32.09% | ||
| Debt/Equity | 0 |
LAB Forecast & Estimates
For the next year, analysts expect an EPS growth of 52.25% and a revenue growth -53.07% for LAB